AzTrials
AzTrials

Sjögren's SyndromeSS-INQNCT04798911

SS-INQ Information Needs Questionnaire in Sjögren's Syndrome

An observational study of Sjögren's Syndrome, run by University College, London at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Patients with some long-standing rheumatic diseases have stated that they want to be fully informed about their disease as they find it 'more scary not to know' about possible complications and consequences. Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Sjögren's Syndrome
What is being tested?
Phase 1 Observational Interviews
How many people
243 participants
Where
1 siteUnited Kingdom
Study dates
12 Oct 2018to 21 Jul 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Sjögren's Syndrome above 18 years old.

Who may be able to join

  • Adult patients with a diagnosis of primary SS as per the 2002 American-European Consensus Group (AECG) classification criteria, or
  • Adult patients with a diagnosis of primary SS as per the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria
  • Adults with the capacity to consent to their involvement in the study
  • Willingness to participate in focus groups
  • Fluency in the English language to allow participation in focus group discussion
  • Willingness to complete the newly developed questionnaire on at least on occasion

Who cannot join

  • Patients with SS who have developed lymphomatous chang

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • University College London Hospitals NHS Foundation Trust

    London, NW1 2BU

Other trials in United Kingdom

About this study

Official title: Defining the Informational Needs of Patients With Sjögren's Syndrome and Development of a Sjögren's Syndrome-specific Informational Needs Questionnaire (SS-INQ)

Patients with some long-standing rheumatic diseases have stated that they want to be fully informed about their disease as they find it 'more scary not to know' about possible complications and consequences. Patients who have the information they want about their disease can fully take part in decisions about their own health creating a partnership with their doctor. Sjögren's Syndrome (SS) is a multi-system, long-standing rheumatic disease that has a negative impact on the daily life of patients. A common presentation of this disease is dry mouth, which can make talking, eating and swallowing more difficult.

Project aims: We aim to ask patients with SS what information they think it would be important to know about SS. We plan to create a questionnaire that can be used by doctors to help deliver the right information to patients at hospital visits.

Timescale: This project will take 36 months to complete. Clinical relevance: This questionnaire could be used in daily practice. It could help patients cope with their disease, take part in treatment decision and reduced uncertainty and distress.

Read the detailed description

This is a PhD student project that will be undertaken in 2 distinct phases.

Phase 1:

Determination of Informational Needs (Months 0- 9)

  • Qualitative interviews with patients with SS
  • Interview transcriptions and thematic analysis

Subjects The perspective of the patient is critical in the determination of the informational needs of patients with SS. Qualitative interviews will be conducted patients with SS. Due to the depth of rich data that can be derived from focus groups we plan on using this method of qualitative interview.

Streiner and Norman proposed that each focus groups would contain 6 to 12 patients. Approximately 40-50 patients with SS will be recruited for the qualitative interviews. These patients will be identified from the Oral Medicine clinics of the UCLH Eastman Dental Hospital. Inclusion criteria will include:

  • Adult patients with a diagnosis of primary SS as per the 2002 American-European Consensus Group (AECG) classification criteria, or
  • Adult patients with a diagnosis of primary SS as per the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria
  • Adult patients who are able to consent to being involved in the study
  • Willingness to participate in focus groups
  • Fluency of the English language to allow participation in focus groups

Research methods:

These focus groups will take the form of semi-structured interviews, using a topic guide as a general framework during the interview. The topic guide will consist of a list of topics of interest, developed by -

  • informal interviews / discussions with patients and clinicians
  • clinical observation The order of the items on the list will not be fixed and, therefore, will allow for flow of the conversation.

With the qualitative interviews data collection is carried out and analysed in stages. This process continues until data saturation has been achieved. Data saturation is deemed to have been achieved when no new information or themes emerge. Once data saturation has been achieved the digital recordings of the focus groups will then be transcribed to allow analysis of the data.

Data analysis:

Although multiple approaches to qualitative data analysis exist, three are more commonly used, namely thematic analysis, grounded theory and framework analysis. Thematic analysis will be used and the emergent themes will allow for the determination of the informational needs of patients with SS.

Phase 2 Development of the informational need instrument for SS [SS-INQ] (Months 9-32)

  • Adaptation of TINQ-BC for use in patients with SS - generation of relevant questions using themes from Phase 1 qualitative study (removal of those solely related to breast cancer from TINQ-BC) by the expert group
  • Pilot testing of SS-INQ for content and readability will be done via focus groups whilst structural validity will be explored using factor analysis
  • Testing of SS-INQ for reliability - internal consistency reliability and test-retest reliability Subjects (including justification for sample size) The number of experts involved in item generation of a new instrument varies widely in the literature, from as few a 3 to as many as 24. With no established consensus on the critical number of persons involved it is our intention to establish a 5 to 7 person expert group, consisting of Rheumatologists, Oral Medicine Clinicians and Ophthalmologists, to be involved in the generation of questionnaire items.

A previously mentioned we propose to hold focus groups with 6 to 12 patients per group. Approximately 12 to 24 patients with SS will be recruited for content validity and readability.

Tinsley and Tinsley (48) suggest a ratio of about 5 - 10 subjects per question in the instrument up to 300 subjects when carrying out factor analysis. TINQ-BC consists of 52 items, therefore assuming that the SS-INQ will consist of a similar number of items a minimum of 260 patients will be required to determine the structural validity of the newly developed instrument using factor analysis.

The COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) checklist can be used to determine the methodological quality of measurement tools. According to Mokkink et al 50-100 patients to achieve a good to excellent quality assessment rating when determining internal consistency reliability and test-retest reliability.

Research methods and data analysis:

Due to the importance of an underlying structural framework in the development of a questionnaire we plan to adapt an existing informational needs questionnaire, which was developed used Lazarus and Folkman's Theory of Stress and Coping conceptual framework. TINQ-BC was developed in the late 1990s due to a lack of knowledge about the amount and type of information patients with a recent diagnosis of breast cancer may require. In a recent review TINQ- BC was deemed to be a tool that should be used as a model in the development of future informational needs questionnaires. The themes derived from the qualitative interviews will be used to populate the instrument ensuring it is specific to SS and reflective of the patients' informational needs.

The SS-INQ instrument will then be tested for content and structural validity, readability and reliability as follows:

  • Content validity and readability: content validity refers to the extent to which the items in the questionnaire reflect the facets of the domain or construct they are proposed to represent. Each facet of the domain should therefore be represented by at least one item in the questionnaire.
  • Structural validity: factor analysis will be conducted to determine the dimensionality of the instrument. The goal of factor analysis, according to Kin and Mueller, is 'to represent a set of variables in terms of a smaller number of hypothetical variables'.
  • Internal consistency reliability: defined as 'the precision of a scale, based on the homogeneity of the scale's items at one point in time', will be determined by calculating Cronbach's Alpha coefficient. Alpha values can range from 0.0 to 1.0. It refers to the degree to which statements in SSINQ correlate with each other. According to De Vellis and Streiner and Norman levels between 0.7 and 0.9 are desirable.
  • Test-retest Reliability: Test-retest reliability measures reliability of the instrument selected over time. In general instruments are administered at two points in time. A period of 12 to 14 days is generally considered an acceptable retest interval. Anastasi and Urbina suggested that the value of the intraclass correlation coefficient (ICC) should generally be > 0.8 . We will administer the chosen instrument at two time points 14 days apart. The ICC will then be calculated.

Final analysis 32-36 months.

Being tested
Phase 1 Observational Interviews
Medical subject headings
Sjogren's Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Phase 1 Observational InterviewsOther

    Qualitative interviews with patients with SS

Study groups in NCT04798911
Study groupRoleWhat they receive
Observational - phase 1Determination of Informational Needs (Months 0- 9) * Qualitative interviews with patients with SS * Interview transcriptions and thematic analysis
Receives: Other: Phase 1 Observational Interviews
Observational - phase 2Phase 2 Development of the informational need instrument for SS [SS-INQ] (Months 9-32) * Adaptation of TINQ-BC for use in patients with SS - generation of relevant questions using themes from Phase 1 qualitative study (removal of those solely related to breast cancer from TINQ-BC) by the expert group * Pilot testing of SS-INQ for content and readability will be done via focus groups whilst structural validity will be explored using factor analysis * Testing of SS-INQ for reliability - internal consistency reliability and test-retest reliability
Receives: Other: Phase 1 Observational Interviews

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determine information needs of patients with SS and develop a new questionnaire

    Qualitative interviews with patients with SS Interview transcriptions and thematic analysis Adaptation of TINQ-BC for use in patients with SS - generation of relevant questions using themes from Phase 1 qualitative study (removal of those solely related to breast cancer from TINQ-BC) by the expert group Pilot testing of SS-INQ for content and readability will be done via focus groups whilst structural validity will be explored using factor analysis Testing of SS-INQ for reliability - internal consistency reliability and test-retest reliability

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Mar 2021
  2. Study start12 Oct 2018
  3. Primary completion21 Jul 2021
  4. Study completion21 Jul 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Other
Enrolment
243 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04798911
Sponsor's protocol ID
226947
Acronym
SS-INQ
Status last verified
Mar 2021
First submitted
5 Mar 2021
Last updated
12 Oct 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Sjögren's Syndrome, run by University College, London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determine information needs of patients with SS and develop a new questionnaire (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in